BiVictriX Announces FDA Orphan Drug Designation and Completion of FDA INTERACT Meeting for BVX001 in the Treatment of Acute Myeloid Leukemia
Alderley Park, 17 April 2024– BiVictriX Therapeutics plc (AIM: BVX), a biotechnology company developing novel, next-generation bispecific Antibody Drug Conjugates (bxADCs) which are designed to offer substantially improved cancer cell...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Acute Leukemia | Acute Myeloid Leukemia | Biotechnology | Cancer | Cancer & Oncology | Clinical Trials | Leukemia | Pharmaceuticals